Notably, CD8+ TIL from anti-PD-1-treated B16F10E-KO was only marginally less enriched with CD103+ T cells than those from isotype-treated B16F10E-KO and anti-PD-1-treated B16F10E tumours (Supplementary Fig. 7a). Here, CD8A is linked to neoplasm.